Solid Biosciences Dirección

Dirección controles de criterios 3/4

El CEO de Solid Biosciences' es Bo Cumbo , nombrado en Dec 2022, tiene una permanencia de 1.33 años. compensación anual total es $3.98M, compuesta por 1.1% salario y 98.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.046% de las acciones de la empresa, por valor de $148.94K. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 6.7 años, respectivamente.

Información clave

Bo Cumbo

Chief Executive Officer (CEO)

US$918.6k

Compensación total

Porcentaje del salario del CEO	63.7%
Permanencia del CEO	1.4yrs
Participación del CEO	0.05%
Permanencia media de la dirección	1.4yrs
Promedio de permanencia en la Junta Directiva	6.8yrs

Actualizaciones recientes de la dirección

Recent updates

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Apr 30

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Apr 28

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Mar 17

Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

Oct 28

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Jul 13

We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Mar 17

Soild Bio sinks 13% after Sarepta data misses goal

Jan 08

Solid Biosciences launches $90M private placement

Dec 11

Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data

Nov 10

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bo Cumbo en comparación con los beneficios de Solid Biosciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$919k	US$585k	-US$96m
Sep 30 2023	n/a	n/a	-US$91m
Jun 30 2023	n/a	n/a	-US$90m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$4m	US$46k	-US$86m

Compensación vs. Mercado: La compensación total de Bo($USD918.55K) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD2.39M).

Compensación vs. Ingresos: La compensación de Bo ha sido consistente con los resultados de la empresa en el último año.

CEO

Bo Cumbo (52 yo)

1.4yrs

Permanencia

US$918,550

Compensación

Mr. Alexander G. Cumbo, also known as Bo, serves as President, Chief Executive Officer and Director at Solid Biosciences Inc. since December 02, 2022. He serves as Independent Director of Verve Therapeutic...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ian Smith	Executive Chair	4.1yrs	US$828.65k	0.27% $ 1.0m
Alexander Cumbo	President	1.4yrs	US$918.55k	0.046% $ 170.0k
Ilan Ganot	Co-founder	11.3yrs	US$902.09k	0.33% $ 1.2m
Kevin Tan	CFO & Treasurer	1.3yrs	US$1.36m	0.025% $ 90.7k
David Howton	COO, General Counsel & Secretary	1.4yrs	US$648.88k	0.020% $ 74.9k
Annie Ganot	Co-Founder & Head of Patient Advocacy	no data	sin datos	sin datos
Paul Herzich	Chief Technology Officer	1.4yrs	sin datos	0.016% $ 58.7k
Jennifer Marlowe	Chief Scientific Officer	less than a year	sin datos	0.018% $ 68.2k
Allison Bogosian	Senior Vice President of Human Resources	2.3yrs	sin datos	sin datos
Jessie Hanrahan	Chief Regulatory Officer	1.4yrs	sin datos	0.018% $ 68.1k
Shuli Kulak	Head of Corporate Strategy & Business Development	less than a year	sin datos	sin datos
Gabriel Brooks	Chief Medical Officer	less than a year	sin datos	sin datos

1.4yrs

Permanencia media

47yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SLDB no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ian Smith	Executive Chair	4.1yrs	US$828.65k	0.27% $ 1.0m
Alexander Cumbo	President	1.4yrs	US$918.55k	0.046% $ 170.0k
Ilan Ganot	Co-founder	11.3yrs	US$902.09k	0.33% $ 1.2m
Jeffrey Bluestone	Member of Scientific Advisory Board	no data	sin datos	sin datos
Rajeev Shah	Independent Director	7.2yrs	US$104.22k	sin datos
Adam Koppel	Independent Director	1.4yrs	US$94.22k	0% $ 0
Jeffrey Chamberlain	Chairman of Scientific Advisory Board	6.3yrs	sin datos	sin datos
Adam Stone	Lead Independent Director	8.5yrs	US$109.72k	0% $ 0
Lynne Sullivan	Independent Director	8.5yrs	US$113.22k	0% $ 0
Carrie Miceli	Member of Scientific Advisory Board	no data	sin datos	sin datos
Ronald Cohn	Member of Scientific Advisory Board	no data	sin datos	sin datos
Dongsheng Duan	Member of Scientific Advisory Board	no data	sin datos	sin datos

6.8yrs

Permanencia media

52.5yo

Promedio de edad

Junta con experiencia: La junta directiva de SLDB se considera experimentada (6.7 años de antigüedad promedio).

Solid Biosciences Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Solid Biosciences Inc., Annual General Meeting, Jun 11, 2024

Solid Biosciences Inc. Appoints Gabriel Brooks as Chief Medical Officer

Solid Biosciences Inc. Announces Executive Changes

Solid Biosciences Appoints Kevin Tan as Chief Financial Officer

Solid Biosciences Inc. Announces Executive Changes

Solid Biosciences Inc. Announces Management Changes

Recent updates

Solid Biosciences Inc., Annual General Meeting, Jun 11, 2024

Buy Solid Biosciences: Unpacking Its Main Value Driver

Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Consensus EPS estimates upgraded to US$2.79 loss

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Solid Biosciences Inc. announced that it expects to receive $108.858551 million in funding from a group of investors

Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate Sgt-003

Consensus revenue estimates decrease by 50%, EPS upgraded

New minor risk - Share price stability

Solid Biosciences Inc. Appoints Gabriel Brooks as Chief Medical Officer

Consensus revenue estimates decrease by 33%, EPS upgraded

New major risk - Revenue size

New minor risk - Market cap size

Solid Biosciences Inc. Announces Executive Changes

First quarter 2023 earnings released: US$1.54 loss per share (vs US$3.37 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Solid Biosciences Inc. and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Solid Biosciences Appoints Kevin Tan as Chief Financial Officer

Solid Biosciences Inc. Announces Executive Changes

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings released: US$2.71 loss per share (vs US$2.40 loss in 3Q 2021)

Third quarter 2022 earnings released: US$2.71 loss per share (vs US$2.40 loss in 3Q 2021)

Consensus forecasts updated

Price target decreased to US$3.00

Solid Biosciences Inc. Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle

Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results

Consensus forecasts updated

Solid Biosciences Inc. (NasdaqGS:SLDB) entered into a definitive agreement to acquire AavantiBio, Inc.

Solid Biosciences to acquire gene therapy company AavantiBio

Bain Capital Engages in Discussions with Solid Biosciences

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Solid Biosciences Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq for Minimum Bid Price Requirement

Price target decreased to US$5.60

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Consensus revenue estimates fall by 12%

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Price target decreased to US$8.67

Solid Biosciences Inc. to Report Q1, 2022 Results on Apr 27, 2022

Price target decreased to US$8.67

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Price target decreased to US$7.40

Price target decreased to US$7.42

Price target decreased to US$8.50

Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

Solid Biosciences Inc. Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

Solid Biosciences Inc. to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

Consensus forecasts updated

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Solid Biosciences Inc.(NasdaqGS:SLDB) dropped from Russell 2500 Growth Index

Co-Founder & Independent Director Matthew Arnold has left the company

Solid Biosciences Inc Announces Two Additional Patients Dosed in the IGNITE DMD Clinical Trial

We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Solid Biosciences Reports Efficacy and Safety Data from the Ongoing Ignite Dmd Clinical Trial and Resumption of Patient Dosing in the 2E14 Vg/Kg Cohort

Solid Biosciences Inc. Announces Management Changes

New 90-day high: US$9.74

CFO & Treasurer has left the company

Co-founder exercised options and sold US$66k worth of stock

Soild Bio sinks 13% after Sarepta data misses goal

New 90-day high: US$7.79

New 90-day high: US$5.60

Solid Biosciences launches $90M private placement

Solid Biosciences Inc. Announces Management Changes

Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data

Solid Biosciences Inc. to Report Q3, 2020 Results on Nov 05, 2020

Solid Biosciences Announces Fda Lifts Clinical Hold on Ignite Dmd Clinical Trial

New 90-day low: US$2.15

New 90-day low - US$2.34